Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.035
Sell
RSI(14)
40.379
Neutral
STOCH(KDJ)(9,3,3)
10.146
Oversold
ATR(14)
0.242
Low Volatility
CCI(14)
-150.079
Sell
Williams %R
100.000
Oversold
TRIX(12,20)
0.008
Sell
StochRSI(14)
0.000
Sell
AC Immune SA
ACIU2.580USD
-0.120-4.44%
Market hours （ET）Quotes delayed by 15 min
139.17MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of AC Immune SA
Currency: USD Updated: 2026-03-27Key Insights
AC Immune SA's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 143 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AC Immune SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
AC Immune SA Highlights
StrengthsRisks
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.52M.
Overvalued
The company’s latest PE is -3.06, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.95M shares, increasing 0.03% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 5.59K shares of this stock.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
9.000
Target Price
+211.42%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of AC Immune SA is 5.75, ranking 322 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 427.20K, representing a year-over-year decrease of 66.86%, while its net profit experienced a year-over-year decrease of 1.42%.
Score
Financials
4.95
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.84
Operational Efficiency
2.84
Growth Potential
6.03
Shareholder Returns
7.08
AC Immune SA's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of AC Immune SA is 5.95, ranking 345 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.06, which is -33.39% below the recent high of -2.04 and -158.63% above the recent low of -7.91.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 143/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of AC Immune SA is 9.50, ranking 5 out of 391 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 12.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
9.000
Target Price
+211.42%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
AC Immune SA
ACIU
4
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of AC Immune SA is 6.52, ranking 208 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.20 and the support level at 2.42, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.854
Sell
MA10
2.961
Sell
MA20
2.937
Sell
MA50
3.048
Sell
MA100
3.105
Sell
MA200
2.782
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of AC Immune SA is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 29.05%, representing a quarter-over-quarter decrease of 0.04%. The largest institutional shareholder is James Simons, holding a total of 668.87K shares, representing 0.66% of shares outstanding, with 17.87% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BVF Partners L.P.
DH Capital GmbH & Co. KG
Varuma AG
Pfeifer (Andrea M. A Ph.D.)
Wells Fargo Advisors
Millennium Management LLC
Acadian Asset Management LLC
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AC Immune SA is 1.90, ranking 267 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.61
VaR
+6.51%
240-Day Maximum Drawdown
+36.84%
240-Day Volatility
+89.40%
Return
Best Daily Return
60 days
+7.51%
120 days
+27.48%
5 years
+71.72%
Worst Daily Return
60 days
-9.97%
120 days
-11.98%
5 years
-19.18%
Sharpe Ratio
60 days
-0.83
120 days
+0.07
5 years
+0.10
Risk Assessment
Maximum Drawdown
240 days
+36.84%
3 years
+70.40%
5 years
+82.32%
Return-to-Drawdown Ratio
240 days
+1.98
3 years
+0.14
5 years
-0.15
Skewness
240 days
+1.02
3 years
+4.62
5 years
+3.48
Volatility
Realised Volatility
240 days
+89.40%
5 years
+89.18%
Standardised True Range
240 days
+7.69%
5 years
+8.63%
Downside Risk-Adjusted Return
120 days
+13.03%
240 days
+13.03%
Maximum Daily Upside Volatility
60 days
+50.67%
Maximum Daily Downside Volatility
60 days
+45.60%
Liquidity
Average Turnover Rate
60 days
+0.13%
120 days
+0.14%
5 years
--
Turnover Deviation
20 days
-53.52%
60 days
-43.85%
120 days
-38.73%
Peer Comparison
Biotechnology & Medical Research
AC Immune SA
ACIU
6.02 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
